title: Catheter-directed thrombolysis for lower extremity deep vein thrombosis.
abstract: The elimination of the embolic potential of existing thrombus, the restoration of unobstructed flow, the prevention of further thrombosis, and the preservation of venous valve function are the ideal goals of therapy for acute deep vein thrombosis (DVT). Meeting these goals will not only prevent pulmonary embolism but will also minimize the long-term sequelae of venous hypertension and the development of postthrombotic syndrome (PTS). Treatment strategies aimed at eliminating or reducing the risk of PTS should focus on preserving valvular function and eliminating the risk of continued venous obstruction after acute DVT. Thrombolytic agents are an attractive form of early therapy because they have the ability to eliminate obstructive thrombus in the deep veins and should therefore help provide protection against PTS. The perceived benefits of early and rapid recanalization in preserving valve function has been the basis for the use of lytic therapy to treat acute DVT.
authors: Wisconsin Heart and Vascular Clinics, Suite 514, 2801 West Kinnickinnic River Parkway, Milwaukee, WI, USA.
authors: M W
authors: MW
authors: Mewissen
mesh_terms: D002408:Catheters, Indwelling; D005268:Femoral Vein / Q000473:pathology / Q000601:surgery; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007084:Iliac Vein / Q000473:pathology / Q000601:surgery; D007866:Leg / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D011994:Recombinant Proteins / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000295:instrumentation* / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000188:drug therapy*
chemical_list: D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D006493:Heparin; C087896:reteplase; D010959:Tissue Plasminogen Activator